2. Academic Validation
  3. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer

Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer

  • Cells. 2019 Jan 11;8(1):43. doi: 10.3390/cells8010043.
Veronica Mollica 1,  Vincenzo Di Nunno 2,  Alessia Cimadamore 3,  Antonio Lopez-Beltran 4,  Liang Cheng 5,  Matteo Santoni 6,  Marina Scarpelli 7,  Rodolfo Montironi 8,  Francesco Massari 9
Affiliations

Affiliations

  • 1 Division of Oncology, S. Orsola-Malpighi Hospital, Bologna 40138, Italy. [email protected].
  • 2 Division of Oncology, S. Orsola-Malpighi Hospital, Bologna 40138, Italy. [email protected].
  • 3 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona 60126, Italy. [email protected].
  • 4 Department of Surgery, Cordoba University Medical School, Cordoba 14071, Spain. [email protected].
  • 5 Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA. [email protected].
  • 6 Oncology Unit, Macerata Hospital, Macerata 62012, Italy. [email protected].
  • 7 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona 60126, Italy. [email protected].
  • 8 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona 60126, Italy. [email protected].
  • 9 Division of Oncology, S. Orsola-Malpighi Hospital, Bologna 40138, Italy. [email protected].
PMID: 30642011 DOI: 10.3390/cells8010043
Abstract

Management of metastatic or advanced prostate Cancer has acquired several therapeutic approaches that have drastically changed the course of the disease. In particular due to the high sensitivity of prostate Cancer cells to hormone depletion, several agents able to inhibit hormone production or binding to nuclear receptor have been evaluated and adopted in clinical practice. However, despite several hormonal treatments being available nowadays for the management of advanced or metastatic prostate Cancer, the natural history of the disease leads inexorably to the development of resistance to hormone inhibition. Findings regarding the mechanisms that drive this process are of particular and increasing interest as these are potentially related to the identification of new targetable pathways and to the development of new drugs able to improve our patients' clinical outcomes.

Keywords

AR splice variants; epigenetic mechanisms; hormone inhibition resistance; prostate cancer (PCa), castration-resistance PCa.

Figures
Products